Literature DB >> 9883478

Steroid therapy in fulminant hepatic failure secondary to autoimmune hepatitis.

E J Viruet1, E A Torres.   

Abstract

Autoimmune hepatitis is a chronic inflammatory liver disorder of unknown etiology associated with serum autoantibodies and hypergammaglobulinemia. This disease has a broad spectrum of presentations ranging from asymptomatic to fulminant hepatic failure. A 36 year old female with past history of hypothyroidism developed jaundice 2 months prior to admission. Outpatient evaluation revealed ANA and anti-SMA antibodies in high titers, negative viral markers for hepatitis, and hypergammaglobulinemia. A presumptive diagnosis of autoimmune hepatitis was made; steroids were recommended but the patient did not take them. She was admitted to the University Hospital due to increased jaundice, general malaise and ascites 5 weeks later. She deteriorated developing coagulopathy, encephalopathy and increasing hyperbilirubinemia. Intravenous corticosteroids were started. The patient improved and was discharged 3 weeks after admission. Fulminant hepatic failure has a high mortality and may require liver transplant. Our patient survived fulminant hepatic failure that resolved after corticosteroid therapy. It is important to identify and distinguish autoimmune hepatitis from other forms of liver disease because of the high percentage of response to immuno-suppressive therapy. Early diagnosis and treatment of this condition could improve survival, quality of life, and defer liver transplantation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9883478

Source DB:  PubMed          Journal:  P R Health Sci J        ISSN: 0738-0658            Impact factor:   0.705


  8 in total

Review 1.  Difficult treatment decisions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  World J Gastroenterol       Date:  2010-02-28       Impact factor: 5.742

2.  Improved survival ratios correlate with myeloid dendritic cell restoration in acute-on-chronic liver failure patients receiving methylprednisolone therapy.

Authors:  Juan Zhao; Ji-Yuan Zhang; Hong-Wei Yu; Yu-Lan He; Jing-Jing Zhao; Juan Li; Yue-Ke Zhu; Qin-Wei Yao; Jin-Huan Wang; Hai-Xia Liu; Shu-Yun Shi; Zheng-Sheng Zou; Xiang-Sheng Xu; Chun-Bao Zhou; Fu-Sheng Wang; Qing-Hua Meng
Journal:  Cell Mol Immunol       Date:  2012-01-09       Impact factor: 11.530

Review 3.  Optimizing management in autoimmune hepatitis with liver failure at initial presentation.

Authors:  Jonathan R Potts; Sumita Verma
Journal:  World J Gastroenterol       Date:  2011-04-28       Impact factor: 5.742

Review 4.  Acute and acute severe (fulminant) autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-10-23       Impact factor: 3.199

Review 5.  Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment.

Authors:  Albert J Czaja; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2009-05-21       Impact factor: 5.742

6.  Clinical heterogeneity in autoimmune acute liver failure.

Authors:  Norberto C Chavez-Tapia; Julio Martinez-Salgado; Julio Granados; Misael Uribe; Felix I Tellez-Avila
Journal:  World J Gastroenterol       Date:  2007-03-28       Impact factor: 5.742

7.  Acute liver failure: Summary of a workshop.

Authors:  William M Lee; Robert H Squires; Scott L Nyberg; Edward Doo; Jay H Hoofnagle
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

8.  Clinical characteristics and treatment outcomes of acute severe autoimmune hepatitis.

Authors:  Linhua Zheng; Yansheng Liu; Yulong Shang; Zheyi Han; Ying Han
Journal:  BMC Gastroenterol       Date:  2021-03-01       Impact factor: 3.067

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.